LoginSignup
profile image
Chris Lee
@Vestin
6Mon·

$IBRX (-0.72%) It's getting nice and slow! There are now also very positive data on the treatment of lung cancer.


IBRX will really shake up current cancer treatment methods.

4
1 Comment
Fuchs89@nit
6Mon
the company was under the radar and oversold for a long time due to the CRL last year. After the long-awaited approval, it still hasn't leaked out what this event means for the future of cancer therapy. The media is not reporting on it, so there is no hype. If a partnership with Merck is announced (or another pharmaceutical giant), it will soon be leaked to the masses. FYI: Anktiva has a 71% success rate in the treatment of bladder cancer (WITHOUT adverse events), compared to Merck's Keytruda, the current standard therapy, with only 42% and sometimes severe side effects and a shorter duration of action
•
2
•
Join the conversation
Sign upLogin